BSEM BioStem Technologies Inc

BioStem Technologies Announces Veterans Day Fundraiser to Support America's VetDogs®

BioStem Technologies Announces Veterans Day Fundraiser to Support America's VetDogs®

Pompano Beach, Fl., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. and its subsidiary Blue Tech Industries, Inc. (d/b/a BioStem Life Sciences), a Certified VOSB (Veteran-Owned Small Business), are proud to announce a 2021 Veterans Day Fundraiser to support America's VetDogs®. To honor those who have served our country, BioStem Technologies will be donating 10% of proceeds from all sales November 10-11th, 2021, to America's VetDogs®

The service dog programs of America's VetDogs® were created to provide enhanced mobility and renewed independence to United States veterans, active-duty service members, and first responders, allowing them to once again live with pride and self-reliance. America's VetDogs® specializes in placing highly skilled service and guide dogs with individuals suffering from physical injuries, PTSD, hearing and vision loss, and seizures. All services are provided by America's VetDogs® at no cost to the individual. 

"We are excited to support this amazing organization and its mission to help those who selflessly served our country live with independence and dignity. As a USMC veteran myself, I have witnessed many brothers and sisters dealing with issues ranging from mental health to physical disabilities resulting from their military service," stated Andrew Van Vurst, BioStem Technologies COO and Co-Founder. "BioStem has had the privilege of providing life-changing tissue allografts to the VA for the last few years, and we are honored once again to help those who serve us by providing quality care for our veterans."

For more information on America's VetDogs® or how you can help support this wonderful organization, please click .

About America's VetDogs®: Since 2003, America's VetDogs () has trained and placed guide and service dogs to provide independence, enhanced mobility, and companionship to veterans with disabilities from all eras. In 2015, VetDogs opened its programs to first responders, including fire, police, and emergency medical personnel. America's VetDogs is a 501(c)(3) not-for-profit organization founded by the Guide Dog Foundation and serves clients from across the United States. VetDogs relies on contributions from generous individuals, corporations, service clubs, and foundations to fund its mission to help those who have served our country live with dignity and independence. It costs over $50,000 to breed, raise, train, and place one assistance dog, but America's VetDogs provides its services completely free of charge to the individual. America's VetDogs has been accredited by both the International Guide Dog Federation and Assistance Dogs International. 

About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local Microenvironment Activation®, or LMA®, uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value. 

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

BioStem Technologies, Inc.

Phone: 954-380-8342

Website: 

Email: 

Twitter: @BSEM_Tech

Facebook: BioStem Technologies

Investor Relations:



(954) 380-8342



EN
01/11/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioStem Technologies Inc

 PRESS RELEASE

BioStem Technologies Reports Third Quarter 2025 Financial Results

BioStem Technologies Reports Third Quarter 2025 Financial Results POMPANO BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported financial results for the third quarter ended September 30, 2025. Recent Business Highlights Achieved 40% growth in product volume quarter-over-quarterReported positive top-line randomized controlled trial results demonstrating superior outcomes with BioREtain® Allografts in diabetic foot ulcers...

 PRESS RELEASE

BioStem Technologies Announces Filing of Restated Financial Statements

BioStem Technologies Announces Filing of Restated Financial Statements POMPANO BEACH, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the filing of its restated interim financial statements for the periods from Q1 2024 through Q2 2025 as well as its restated annual financial statements for 2023 and 2024. “Completing our restated financial statements is a significant milestone for the Company,” said Brandon Poe, CFO of BioS...

 PRESS RELEASE

BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare R...

BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today commented on the Centers for Medicare & Medicaid Services’ (“CMS”) Calendar Year 2026 Physician Fee Schedule (PFS) final rule, which reforms Medicare reimbursement for skin substitutes. “CMS’s final rule represents a decisive step toward a more transparent, predictable, and sustainable reimbursement system...

 PRESS RELEASE

BioStem Technologies Secures Land Purchase at the Research Park at Flo...

BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years  City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the purchase of land for its future headquarters in the Research P...

 PRESS RELEASE

BioStem Technologies Reports Positive Top-Line Clinical Results Demons...

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of care POMPANO BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch